ACTIVE_NOT_RECRUITING

Meaning-Centered Counseling for Chinese Patients Who Are Being Treated for Advanced Cancer

Conditions

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of the study is to modify a type of counseling called "Individual Meaning Centered Psychotherapy" to meet the needs of Chinese cancer patients. Many cancer patients use counseling or other resources to help cope with the emotional burden of their illnesses. Counseling often helps them cope with cancer by giving them a place to express their feelings. "Meaning-Centered" counseling aims to teach cancer patients how to maintain or even increase a sense of meaning and purpose in their lives, despite cancer.

Official Title

Adaptation of Individual Meaning-Centered Psychotherapy for Chinese Immigrant Cancer

Quick Facts

Study Start:2014-04

Study Completion:2027-02-15

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:ACTIVE_NOT_RECRUITING

Study ID

NCT02112188

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:21 Years to 80 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* Non-US born; * Of Chinese descent; * Age 21 years through 80 years; * Language spoken: Mandarin and/or English * Diagnosis of Stage IV cancer (any type). * Stage III or IV cancer (per self-report or on the MSKCC EMR). If traditional staging does not apply (i.e. for leukemia), we can allow patient deemed by provider to have poor prognosis/roughly equivalent to Stage III or IV to be referred. * Age 18 or older * Of Chinese descent * Mandarin-speaking * Have an estimated life expectancy of at least 6 months (per self-report or on the MSKCC EMR) * Resides in New York State or New Jersey * Stage III or IV cancer (per self-report or on the MSKCC EMR). If traditional staging does not apply (i.e. for leukemia), we can allow patient deemed by provider to have poor prognosis/roughly equivalent to Stage III or IV to be referred. * Age 18 or older * Of Chinese descent * Mandarin-speaking * Have an estimated life expectancy of at least 6 months (per referring physician assessment or on the MSKCC EMR) * Resides in New York State or New Jersey	* Presence of cognitive impairment disorder (e.g., delirium or dementia) sufficient to preclude meaningful informed consent and/or data collection. The Chinese version of the Mini Mental State Examination (MMSE) (46) will be used as a cognitive screening tool. Patients with MMSE scores below 20 will be excluded. For English speaking patients we will use the English version of the MMSE. * Has a household member who has already participated (or agreed to participate). * Previous participation in Phases 1 or 2 of the study * Unable/unwilling to use or no access to a telehealth platform (i.e., telephone or videoconference) * For participants who express interest in RSMI, unable/unwilling to use Zoom videoconferencing platform * Unable or unwilling to commit to up to 16 weeks to complete 6-session intervention and follow-up assessments * Major psychiatric illness or cognitive impairment that in the judgment of study investigators or study staff would preclude study participation * Patients diagnosed with primary brain tumors (per self-report or on the MSKCC EMR), as they may have difficulty completing the intervention and answering questionnaires * Undergoing hematopoietic stem cell transplantation (HSCT) (per self-report or on the MSKCC EMR) * Currently in psychotherapeutic treatment (patients being treated with psychotropic medications will not be excluded, as long as they are not in psychotherapy; per self report) * Previous participation in Phases 1, 2, or 3 of the study * Unable/unwilling to use or no access to the Zoom videoconferencing platform (required for RSMI) * Unable or unwilling to commit to up to 16 weeks to complete 6-session intervention and follow-up assessments * Major psychiatric illness or cognitive impairment that in the judgment of study investigators or study staff would preclude study participation * Patients diagnosed with primary brain tumors (per self-report or on the MSKCC EMR), as they may have difficulty completing the intervention and answering questionnaires * Undergoing hematopoietic stem cell transplantation (HSCT) (per self-report or on the MSKCC EMR) * Currently in psychotherapeutic treatment (patients being treated with psychotropic medications will not be excluded, as long as they are not in psychotherapy; per self report)

Inclusion Criteria

Exclusion Criteria

* Non-US born;
* Of Chinese descent;
* Age 21 years through 80 years;
* Language spoken: Mandarin and/or English
* Diagnosis of Stage IV cancer (any type).
* Stage III or IV cancer (per self-report or on the MSKCC EMR). If traditional staging does not apply (i.e. for leukemia), we can allow patient deemed by provider to have poor prognosis/roughly equivalent to Stage III or IV to be referred.
* Age 18 or older
* Of Chinese descent
* Mandarin-speaking
* Have an estimated life expectancy of at least 6 months (per self-report or on the MSKCC EMR)
* Resides in New York State or New Jersey
* Stage III or IV cancer (per self-report or on the MSKCC EMR). If traditional staging does not apply (i.e. for leukemia), we can allow patient deemed by provider to have poor prognosis/roughly equivalent to Stage III or IV to be referred.
* Age 18 or older
* Of Chinese descent
* Mandarin-speaking
* Have an estimated life expectancy of at least 6 months (per referring physician assessment or on the MSKCC EMR)
* Resides in New York State or New Jersey

* Presence of cognitive impairment disorder (e.g., delirium or dementia) sufficient to preclude meaningful informed consent and/or data collection. The Chinese version of the Mini Mental State Examination (MMSE) (46) will be used as a cognitive screening tool. Patients with MMSE scores below 20 will be excluded. For English speaking patients we will use the English version of the MMSE.
* Has a household member who has already participated (or agreed to participate).
* Previous participation in Phases 1 or 2 of the study
* Unable/unwilling to use or no access to a telehealth platform (i.e., telephone or videoconference)
* For participants who express interest in RSMI, unable/unwilling to use Zoom videoconferencing platform
* Unable or unwilling to commit to up to 16 weeks to complete 6-session intervention and follow-up assessments
* Major psychiatric illness or cognitive impairment that in the judgment of study investigators or study staff would preclude study participation
* Patients diagnosed with primary brain tumors (per self-report or on the MSKCC EMR), as they may have difficulty completing the intervention and answering questionnaires
* Undergoing hematopoietic stem cell transplantation (HSCT) (per self-report or on the MSKCC EMR)
* Currently in psychotherapeutic treatment (patients being treated with psychotropic medications will not be excluded, as long as they are not in psychotherapy; per self report)
* Previous participation in Phases 1, 2, or 3 of the study
* Unable/unwilling to use or no access to the Zoom videoconferencing platform (required for RSMI)
* Unable or unwilling to commit to up to 16 weeks to complete 6-session intervention and follow-up assessments
* Major psychiatric illness or cognitive impairment that in the judgment of study investigators or study staff would preclude study participation
* Patients diagnosed with primary brain tumors (per self-report or on the MSKCC EMR), as they may have difficulty completing the intervention and answering questionnaires
* Undergoing hematopoietic stem cell transplantation (HSCT) (per self-report or on the MSKCC EMR)
* Currently in psychotherapeutic treatment (patients being treated with psychotropic medications will not be excluded, as long as they are not in psychotherapy; per self report)

Contacts and Locations

Principal Investigator

Florence Lui, PhD

PRINCIPAL_INVESTIGATOR

Memorial Sloan Kettering Cancer Center

Study Locations (Sites)

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)

Basking Ridge, New Jersey, 07920

United States

Memorial Sloan Kettering Monmouth (Limited Protocol Activities)

Middletown, New Jersey, 07748

United States

Memorial Sloan Kettering Bergen (Limited Protocol Activities)

Montvale, New Jersey, 07645

United States

Memorial Sloan Kettering Cancer Center Suffolk- Commack (Limited Protocol Activities)

Commack, New York, 11725

United States

Memorial Sloan Kettering Westchester (Limited Protocol Activities)

Harrison, New York, 10604

United States

City College of New York (Data Collection AND Data Analysis)

New York, New York, 10031

United States

MSK at Ralph Lauren (Limited Protocol Activities)

New York, New York, 10035

United States

Memorial Sloan Kettering Cancer Center

New York, New York, 10065

United States

Memorial Sloan Kettering Nassau (Limited Protocol Activities)

Uniondale, New York, 11553

United States

Collaborators and Investigators

Sponsor: Memorial Sloan Kettering Cancer Center

Florence Lui, PhD, PRINCIPAL_INVESTIGATOR, Memorial Sloan Kettering Cancer Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2014-04

Study Completion Date2027-02-15

Study Record Updates

Study Start Date2014-04

Study Completion Date2027-02-15

Terms related to this study

Additional Relevant MeSH Terms

Advanced Cancer